Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | IGF1R | P08069 | 2/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30964777 | 1.00 | KDM4E (0.61) | KDM4EMAPTALDH1A1POLBNPC1 | |
| SCHEMBL30979649 | 0.83 | KDM4E (0.53) | KDM4EMAPTALDH1A1POLBHTT | |
| SCHEMBL27507138 | 0.83 | KDM4E (0.53) | KDM4EMAPTALDH1A1POLBHTT | |
| SCHEMBL6174942 | 0.82 | KDM4E (0.47) | KDM4EMAPTALDH1A1POLBNPC1 | |
| SCHEMBL15919425 | 0.82 | ACACA (0.48) | KDM4EMAPTALDH1A1NPC1HTT | |
| SCHEMBL2998020 | 0.80 | KDM4E (0.50) | KDM4EMAPTALDH1A1POLBHTT | |
| SCHEMBL13576841 | 0.78 | ACLY (0.47) | KDM4EMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL5910669 | 0.77 | KDM4E (0.53) | KDM4EMAPTALDH1A1POLBNPC1 | |
| SCHEMBL5235583 | 0.76 | KDM5A (0.48) | KDM4EMAPTALDH1A1HTTUSP2 | |
| SCHEMBL15919413 | 0.76 | TP53 (0.56) | KDM4EMAPTALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825124-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-11-02 | — | — | US | disclosed |
| US-7786123-B2 | Indolylmaleimide derivatives | ALBERT RAINER | 2010-08-31 | — | — | US | disclosed |
| US-20090318463-A1 | Indolylmaleimide Derivatives | ALBERT RAINER | 2009-12-24 | — | — | US | disclosed |
| EP-1337527-B1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| EP-2070921-A1 | Indolylmaleimide derivatives as protein kinase c inhibitors | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | ALBERT RAINER | 2007-08-16 | — | — | US | disclosed |
| US-20070184061-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-08-09 | — | — | US | disclosed |
| US-20070155817-A1 | Indolylmaleimide derivatives | ALBERT RAINER | 2007-07-05 | — | — | US | disclosed |
| US-7220774-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2007-05-22 | — | — | US | disclosed |
| US-20040053949-A1 | Indolylmaleimide derivatives | ALBERT RAINER (CH) | 2004-03-18 | — | — | US | disclosed |
| US-6645970-B2 | Preventing T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer | NOVARTIS AG (CH) | 2003-11-11 | — | — | US | disclosed |
| EP-1337527-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | Novartis AG (CH) | 2003-08-27 | — | — | EP | disclosed |
| US-20030069424-A1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2003-04-10 | — | — | US | disclosed |
| WO-2002038561-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318463-A1 | Indolylmaleimide Derivatives | NFATC1, INMT, IDO1 | KDM4E 404/4885MAPT 2909/4885ALDH1A1 1752/4885 |
| US-20070191401-A1 | Transplant rejection, autoimmune disease, autoimmune disease | NFATC1, HLA-DRB1, INMT | KDM4E 832/4885MAPT 3568/4885ALDH1A1 1866/4885 |
| US-20030069424-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | KDM4E 404/4885MAPT 2909/4885ALDH1A1 1752/4885 |
| US-20040053949-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | KDM4E 404/4885MAPT 2909/4885ALDH1A1 1752/4885 |
| US-20070155817-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | KDM4E 404/4885MAPT 2909/4885ALDH1A1 1752/4885 |
| US-20070184061-A1 | Indolylmaleimide derivatives | NFATC1, INMT, IDO1 | KDM4E 404/4885MAPT 2909/4885ALDH1A1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.